Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.43 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5359718 | 0.89 | EGFR (0.62) | EGFRABCG2TTBK1TTBK2KDR | |
| SCHEMBL5355580 | 0.87 | AHR (0.52) | EGFRAHRKDRGSK3BRAF1 | |
| SCHEMBL5362131 | 0.81 | ALK (0.45) | EGFRABCG2TTBK1TTBK2KDR | |
| SCHEMBL14355895 | 0.80 | GSK3B (0.47) | EGFRKDRGSK3B | |
| SCHEMBL5358390 | 0.79 | ABCG2 (0.53) | ABCG2KDRGSK3BRAF1BRAF | |
| SCHEMBL5355467 | 0.77 | EGFR (0.58) | EGFRTTBK1TTBK2KDRGSK3B | |
| SCHEMBL18349251 | 0.77 | EGFR (0.77) | EGFRABCG2AHRRAF1BRAF | |
| SCHEMBL5354535 | 0.75 | KDR (0.46) | EGFRKDRGSK3BRAF1BRAF | |
| SCHEMBL5354432 | 0.74 | MEN1 (0.45) | KDRGSK3B | |
| SCHEMBL5356238 | 0.74 | GABRP (0.48) | EGFRKDRGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294633-B2 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2007-11-13 | — | — | US | claimed |
| EP-1390371-B1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2006-03-08 | — | — | EP | claimed |
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | NOVARTIS AG (CH) | 2004-08-05 | — | — | US | claimed |
| EP-1390371-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | Novartis AG (CH) | 2004-02-25 | — | — | EP | claimed |
| WO-2002092603-A1 | OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS | NOVARTIS AG (CH) | 2002-11-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152892-A1 | Oxazolo-and furopyrimidines and their use in medicaments against tumors | DPYD, COXFA4L2, MSH2 | EGFR 1321/4885ABCG2 518/4885AHR 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.